Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (1278)	9/23/1998 10:13:00 PM
From: crysball	Read Replies (1) of 1491

Robert Buzzell -NBC News I wrote NBC News Science and Medical editors about the upcoming HU-211 presentations of Phase 2 clinical trial data. A potentially efficacious drug to treat Brain Trauma and Stroke developed by a small unknown Israeli company ........after years of failure by all the major pharmaceutical companies.....has a 'David vs. Goliath" appeal.....as well as treating the previously untreatable. I also suggested they contact PARS adn/or read this thread (minus the Robert Silver diatribes). While the Seattle conference is for the presentation of scientific data it wouldn't hurt to have science and/or medical editors of the major media in the audiences. If nothing else they are building their file on Pharmos. Ariella, David, Yosi, et al.....perhaps you might have some appropriate media contacts who would find the HU-211 story of interest to their readers. Best regards Neil

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next